Literature DB >> 17016555

To be or not to be B7.

Xingxing Zang1, James P Allison.   

Abstract

The activation of lymphocytes and development of adaptive immune responses is initiated by the engagement of TCRs by antigenic peptide-MHC complexes and shaped at the clonal level by both positive and negative costimulatory signals. The B7 family members are involved at several stages in this process. In this issue of the JCI, Vogt et al. show that the B7 family-related protein V-set and Ig domain-containing 4 (VSIG4) can act as an inhibitor of T cell activation (see the related article beginning on page 2817). Intriguingly, the same molecule was recently independently identified as a complement receptor of the Ig superfamily (CRIg) and was convincingly demonstrated to be a receptor for complement component 3 fragments. These findings raise interesting questions regarding the physiological roles and mechanisms of action of this molecule. Identification of dual functions of this molecule provides an additional level of complexity in T cell costimulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016555      PMCID: PMC1578606          DOI: 10.1172/JCI30103

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Cloning of Z39Ig, a novel gene with immunoglobulin-like domains located on human chromosome X.

Authors:  K Langnaese; L Colleaux; D U Kloos; M Fontes; P Wieacker
Journal:  Biochim Biophys Acta       Date:  2000-07-24

Review 2.  The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function.

Authors:  V M Holers; T Kinoshita; H Molina
Journal:  Immunol Today       Date:  1992-06

3.  Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D.

Authors:  K Hong; T Kinoshita; P Pramoonjago; Y U Kim; T Seya; K Inoue
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

Review 4.  Complement receptors and phagocytosis.

Authors:  E J Brown
Journal:  Curr Opin Immunol       Date:  1991-02       Impact factor: 7.486

5.  The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes.

Authors:  Christof Wagner; Carsten Ochmann; Margarita Schoels; Thomas Giese; Sabine Stegmaier; Rosi Richter; Friederike Hug; G Maria Hänsch
Journal:  Mol Immunol       Date:  2006-02       Impact factor: 4.407

6.  Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. II. Development of syngeneic cytotoxicity in the absence of specific antigenic stimulation.

Authors:  M H Claesson; R G Miller
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

7.  VSIG4, a B7 family-related protein, is a negative regulator of T cell activation.

Authors:  Lorenz Vogt; Nicole Schmitz; Michael O Kurrer; Monika Bauer; Heather I Hinton; Silvia Behnke; Dominique Gatto; Peter Sebbel; Roger R Beerli; Ivo Sonderegger; Manfred Kopf; Philippe Saudan; Martin F Bachmann
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

8.  Characterization of monoclonal antibody specific to the Z39Ig protein, a member of immunoglobulin superfamily.

Authors:  Jin-Kyung Kim; Eun Mi Choi; Hyo-Il Shin; Chang H Kim; Sun-Hee Hwang; Seong-Mi Kim; Byoung S Kwon
Journal:  Immunol Lett       Date:  2005-03-25       Impact factor: 3.685

9.  Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.

Authors:  J D Gray; D A Horwitz
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

10.  Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes.

Authors:  D D Yaskanin; L F Thompson; F J Waxman
Journal:  Cell Immunol       Date:  1992-06       Impact factor: 4.868

View more
  7 in total

Review 1.  Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.

Authors:  Yuzuru Ikehara; Masahiro Yamanaka; Takashi Yamaguchi
Journal:  J Biomed Biotechnol       Date:  2010-06-17

2.  Costimulatory molecule VSIG4 exclusively expressed on macrophages alleviates renal tubulointerstitial injury in VSIG4 KO mice.

Authors:  Yan Li; Yi-Qin Wang; Dai-Hong Wang; Wei-Ping Hou; Ying Zhang; Ming Li; Fu-Rong Li; Jiao Mu; Xiang Du; Fang Pang; Fa-Huan Yuan
Journal:  J Nephrol       Date:  2014-01-15       Impact factor: 3.902

3.  Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression.

Authors:  Baohua Zhao; Aihua Song; Rizwanul Haque; Fengyang Lei; Lauren Weiler; Xiaofang Xiong; Yuzhang Wu; Michael Croft; Jianxun Song
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

4.  Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis.

Authors:  Fang Zheng; Amanda Sparkes; Patrick De Baetselier; Steve Schoonooghe; Benoit Stijlemans; Serge Muyldermans; Véronique Flamand; Jo A Van Ginderachter; Nick Devoogdt; Geert Raes; Alain Beschin
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

Review 5.  Nanobodies for Medical Imaging: About Ready for Prime Time?

Authors:  Léa Berland; Lauren Kim; Omar Abousaway; Andrea Mines; Shruti Mishra; Louise Clark; Paul Hofman; Mohammad Rashidian
Journal:  Biomolecules       Date:  2021-04-26

6.  Human Dendritic Cells Express the Complement Receptor Immunoglobulin Which Regulates T Cell Responses.

Authors:  Usma Munawara; Khalida Perveen; Annabelle G Small; Trishni Putty; Alex Quach; Nick N Gorgani; Charles S Hii; Catherine A Abbott; Antonio Ferrante
Journal:  Front Immunol       Date:  2019-12-10       Impact factor: 7.561

7.  VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism.

Authors:  Jialin Li; Bo Diao; Sheng Guo; Xiaoyong Huang; Chengying Yang; Zeqing Feng; Weiming Yan; Qin Ning; Lixin Zheng; Yongwen Chen; Yuzhang Wu
Journal:  Nat Commun       Date:  2017-11-06       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.